Chart of the week: BTG heading for patent cliff
The UK's largest quoted biotech BTG (BTG) has a growth problem which a forward price/earnings (PE) ratio of 39.6 fails to discount. Despite the imminent launch of Varithena in the US, the varicose vein treatment is not expected to...
10 April 2014
